Tag Archives: substance abuse

Drug courts

Drug courts are judicially supervised court dockets that provide a sentencing alternative of treatment combined with supervision for people living with serious substance use and mental health disorders. Drug courts are problem-solving courts that take a public health approach using a specialized model in which the judiciary, prosecution, defense bar, probation, law enforcement, mental health, social service, and treatment communities work together to help addicted offenders into long-term recovery. 21789-113979

An Indiana drug court graduate looks back three years and sees her former self as someone sad and sick. 

In her jail booking photo from three years ago, you can still see the red mark on Faith Spriggs’ left arm where she injected methamphetamine.

Dressed in an orange jumpsuit, her face is droopy, eyes slightly downcast. In the photo, she’s still high. She had just gone to someone’s house to see if she could score more meth when police stopped her and found drugs and a syringe in her purse.

Now, Spriggs looks at the photo and sees someone who looks sad and sick.

Three years later, she’s a graduate of Noble County Drug Court and hasn’t used for 32 months. She shared the photo — with pride — with the large crowd gathered during her graduation Dec. 5 to show how far she’s come. Read the rest HERE.

Advertisements

Narrow Indication for Abuse-Deterrent Morphine

The latest opioid approved by FDA will be “expected” to reduce abuse by only one route — injection — in its official labeling.

In a carefully-worded press release, drugmaker Egalet said its extended-release morphine drug Arymo ER “increased resistance to cutting, crushing, grinding or breaking using a variety of tools. Due to its physical and chemical properties, Arymo ER is expected to make abuse by injection difficult.” 1pillst

In an FDA advisory committee meeting last year, participants voted that the drug could deter abuse via the oral, nasal, and intravenous routes of abuse. But there were several reasons only the intravenous route won labeling.

An FDA spokesperson told MedPage Today that MorphaBond, another morphine product, has “marketing exclusivity for labeling describing the expected reduction of abuse of single-entity, extended-release morphine by the intranasal route due to physicochemical properties.” MORE HERE